Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.

BioAge Labs has dosed the first subject in the Phase I study of BGE-102, under development initially for treating obesity.

Reunion Neuroscience will be advancing its psychedelic therapy RE104 to a Phase III trial in post-partum depression (PPD) in ...

THL Partners has announced its agreement to purchase Headlands Research, a clinical trial sites network, from KKR-managed ...

MASLD is among the most common types of chronic liver disease and is estimated to affect 30% of the global population.

As antimicrobial resistance (AMR) escalates and chronic viral infections like human immunodeficiency virus (HIV) and herpes ...

Vendanta's CEO also announced the company is cutting 20% of its workforce as a result of the Phase II UC trial failure.

Aligos has initiated dosing in the Phase II B-SUPREME trial of its ALG-000184 in people with chronic hepatitis B virus (HBV) ...

The device for endotoxic septic shock was first approved in Europe more than 20 years ago, in 1994, by Toray Industries.

The Phase II STARLIGHT study (NCT05417126) found that a single intravitreal injection of gene-agnostic MCO-010 in six ...

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.